Clinical Trial Update: Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of Abexinostat and Ibrutinib in diffuse large B-cell lymphoma and mantle cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Abexinostat (Abexinostat)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma | Phase 1 | Status: COMPLETED